drugset

drugset / Trial / NCT00062582

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

NCT00062582 ↗

Phase 3 Completed 1000 enrolled AstraZeneca

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.

Timeline

Start: 2003-06
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Roflumilast	Small molecule	500 ug	—

Indications